Clinical trials: Pembrolizumab, completed
Healthy Male Subjects
Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects
to Compare the Pharmacokinetics and Safety of BAT3306 versus KEYTRUDA® Administered in Healthy Male Subjects
- Trial name
- NCT06111196
- Testing
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, Pembrolizumab injection
- Where
- China
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer…
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Trial name
- NCT04674306
- Testing
- α-lactalbumin vaccine, Zymosan
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- George T. Budd
Carcinoma of Unknown Primary
Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)
Abbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis carcinoma of unknown primary site Trial…
- Trial name
- CUP (NCT03391973)
- Testing
- Pembrolizumab Injection
- Where
- 3 sites in Canada
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- AHS Cancer Control Alberta
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
- Trial name
- NCT04490564
- Testing
- PD-L1 Kit
- Where
- 6 sites in Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Non-small Cell Lung Cancer, Metastatic Lung Cancer
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Investigators are building an empirical evidence base supporting the utility of real-world data through the emulation of randomized controlled trials in the oncology setting.
- Trial name
- NCT05908799
- Testing
- Pembrolizumab + Pemetrexed-Platinum, Pemetrexed-Platinum
- Where
- United States
- Volunteers
- 1,854 people, healthy volunteers welcome
- Sponsor
- Aetion, Inc.
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
This phase II trial studies how well pembrolizumab works in preventing lung cancer patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT03634241
- Testing
- Pembrolizumab, Quality-of-Life Assessment, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Malignant Melanoma
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
An observational single center study designed to identify response-related biomarkers of anti-programmed death 1 (PD-1) therapy to advanced melanoma patients and to investigate if vitamin D levels are related to treatment…
- Trial name
- NCT03197636
- Testing
- Pembrolizumab
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Carcinoma, Non-Small-Cell Lung, Immunotherapy
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.
- Trial name
- PEMBREIZH (NCT05321212)
- Where
- 2 sites in France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
NSCLC Stage IV
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China.
- Trial name
- NCT04076228
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Kiang Wu Hospital